The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Induction of CD8+T-Cell Responses Against Novel Glioma–Associated Antigen Peptides and Clinical Activity by Vaccinations With α-Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma
Open accessAbstract
Purpose: A phase I/II trial was performed to evaluate the safety and immunogenicity of a novel vaccination with α-type 1 polarized dendritic cells (αDC1) loaded with synthetic peptides for glioma-associated antigen (GAA) epitopes and administration of polyinosinic-polycytidylic acid [poly(I:C)] stabilized by lysine and carboxymethylcellulose (poly-ICLC) in HLA-A2+patients with recurrent malignant gliomas. GAAs for these peptides are EphA2, interleukin (IL)-13 receptor-α2, YKL-40, and gp100. Patients and Methods: Twenty-two patients (13 with glioblastoma multiforme [GBM], five with anaplastic astrocytoma [AA], three with anaplastic oligodendroglioma [AO], and one with anaplastic oligoastrocytoma [AOA]) received at least one vaccination, and 19 patients received at least four vaccinations at two αDC1 dose levels (1 × or 3 × 10 7/dose) at 2-week intervals intranodally. Patients also received twice weekly intramuscular injections of 20 μg/kg poly-ICLC. Patients who demonstrated positive radiologic response or stable disease without major adverse events were allowed to receive booster vaccines. T-lymphocyte responses against GAA epitopes were assessed by enzyme-linked immunosorbent spot and HLA-tetramer assays. Results: The regimen was well-tolerated. The first four vaccines induced positive immune responses against at least one of the vaccination-targeted GAAs in peripheral blood mononuclear cells in 58% of patients. Peripheral blood samples demonstrated significant upregulation of type 1 cytokines and chemokines, including interferon-α and CXCL10. Nine (four GBM, two AA, two AO, and one AOA) achieved progression-free status lasting at least 12 months. One patient with recurrent GBM demonstrated sustained complete response. IL-12 production levels by αDC1 positively correlated with time to progression. Conclusion: These data support safety, immunogenicity, and preliminary clinical activity of poly-ICLC-boosted αDC1-based vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 655
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
Kaliński, P., Hilkens, C. M., Snijders, A., Snijdewint, F. G., & Kapsenberg, M. L. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.1.28 · Cited by 602
Liau, L. M., Prins, R. M., Kiertscher, S. M., Odesa, S. K., Kremen, T. J., Giovannone, A. J., Lin, J.-W., Chute, D. J., Mischel, P. S., Cloughesy, T. F., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0464 · Cited by 543
Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H. M., Kubo, R. T., Sette, A., et al. (1994) · Immunity · doi:10.1016/s1074-7613(94)80017-0 · Cited by 523
α-Type-1 Polarized Dendritic Cells
Mailliard, R. B., Wankowicz-Kalinska, A., Cai, Q., Wesa, A., Hilkens, C. M., Kapsenberg, M. L., Kirkwood, J. M., Storkus, W. J., & Kalinski, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1261 · Cited by 470
Self-citationYamanaka, R., Homma, J., Yajima, N., Tsuchiya, N., Sano, M., Kobayashi, T., Yoshida, S., Abe, T., Narita, M., Takahashi, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0120 · Cited by 325
Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients
Wheeler, C. J., Black, K. L., Liu, G., Mazer, M., Zhang, X.-X., Pepkowitz, S., Goldfinger, D., Ng, H., Irvin, D., & Yu, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5973 · Cited by 296
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., Herndon, J. E., Lally-Goss, D., McGehee-Norman, S., Paolino, A., Reardon, D. A., Friedman, A. H., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0124 · Cited by 287
Expression of p53 and Prognosis in Children with Malignant Gliomas
Pollack, I. F., Finkelstein, S. D., Woods, J., Burnham, J., Holmes, E. J., Hamilton, R. L., Yates, A. J., Boyett, J. M., Finlay, J. L., & Sposto, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012224 · Cited by 281
Self-citationDe Vleeschouwer, S., Fieuws, S., Rutkowski, S., Van Calenbergh, F., Van Loon, J., Goffin, J., Sciot, R., Wilms, G., Demaerel, P., Warmuth-Metz, M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4875 · Cited by 271
Kaliński, P., Schuitemaker, J. H. N., Hilkens, C. M. U., et al. (1999) · PubMed · Cited by 257
Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.
Debinski, W., Gibo, D. M., Hulet, S. W., Connor, J. R., & Gillespie, G. Y. (1999) · PubMed · Cited by 254
Szczepanski, M. J., Czystowska, M., Szajnik, M., Harasymczuk, M., Boyiadzis, M., Kruk-Zagajewska, A., Szyfter, W., Zeromski, J., & Whiteside, T. L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3838 · Cited by 253
Self-citationRodrigues, J. C., Gonzalez, G. C., Zhang, L., Ibrahim, G., Kelly, J. J., Gustafson, M. P., Lin, Y., Dietz, A. B., Forsyth, P. A., Yong, V. W., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop023 · Cited by 244
Izumoto, S., Tsuboi, A., Oka, Y., Suzuki, T., Hashiba, T., Kagawa, N., Hashimoto, N., Maruno, M., Elisseeva, O. A., Shirakata, T., et al. (2008) · Journal of Neurosurgery · doi:10.3171/jns/2008/108/5/0963 · Cited by 217
Kaliński, P., Schuitemaker, J. H. N., Hilkens, C. M. U., Wierenga, E. A., & Kapsenberg, M. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.6.3231 · Cited by 211
Self-citationSalgaller, M. L., Marincola, F. M., Cormier, J. N., & Rosenberg, S. A. (1996) · PubMed · Cited by 208
Pelloski, C. E., Mahajan, A., Maor, M., Chang, E. L., Woo, S., Gilbert, M., Colman, H., Yang, H., Ledoux, A., Blair, H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1765 · Cited by 207
Kikuchi, T., Akasaki, Y., Abe, T., Fukuda, T., Saotome, H., Ryan, J. L., Kufe, D. W., & Ohno, T. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00005 · Cited by 204
HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells
Liu, G., Ying, H., Zeng, G., Wheeler, C. J., Black, K. L., & Yu, J. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3504 · Cited by 198
Zhu, X., Nishimura, F., Sasaki, K., Fujita, M., Dusak, J. E., Eguchi, J., Fellows-Mayle, W., Storkus, W. J., Walker, P. R., Salazar, A. M., et al. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-10 · Cited by 194
Self-citationBedrosian, I., Mick, R., Xu, S., Nisenbaum, H., Faries, M., Zhang, P., Cohen, P. A., Koski, G., & Czerniecki, B. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.042 · Cited by 174
Immunotherapeutic Approaches for Glioma
Okada, H., Kohanbash, G., Zhu, X., Kastenhuber, E. R., Hoji, A., Ueda, R., & Fujita, M. (2009) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v29.i1.10 · Cited by 171
Self-citationAbility of Mature Dendritic Cells to Interact with Regulatory T Cells Is Imprinted during Maturation
Muthuswamy, R., Urban, J., Lee, J.-J., Reinhart, T. A., Bartlett, D., & Kalinski, P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6818 · Cited by 162
Self-citationDebinski, W., & Gibo, D. M. (2000) · Molecular Medicine · doi:10.1007/bf03401786 · Cited by 142
Kirkwood, J. M., Lee, S., Moschos, S. J., Albertini, M. R., Michalak, J. C., Sander, C., Whiteside, T. L., Butterfield, L. H., & Weiner, L. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1231 · Cited by 138
Self-citationChianese‐Bullock, K. A., Pressley, J., Garbee, C. F., Hibbitts, S., Murphy, C., Yamshchikov, G. V., Petroni, G. R., Bissonette, E. A., Neese, P. Y., Grosh, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.3080 · Cited by 134
Okada, H., Lieberman, F. S., Walter, K. A., Lunsford, L. D., Kondziolka, D. S., Bejjani, G. K., Hamilton, R. L., Torres-Trejo, A., Kaliński, P., Cai, Q., et al. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-67 · Cited by 130
Self-citationSalazar, A. Μ., Levy, H. B., Ondra, S., Kende, M., Scherokman, B., Brown, D. S., Mena, H., Martin, N. S., Schwab, K. A., Donovan, D., et al. (1996) · Neurosurgery · doi:10.1227/00006123-199606000-00006 · Cited by 129
Self-citationElucidating the elite: mechanisms of control in HIV-1 infection
O’Connell, K. A., Bailey, J. R., & Blankson, J. N. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.005 · Cited by 126
Okano, F., Storkus, W. J., Chambers, W. H., Pollack, I. F., & Okada, H. (2002) · PubMed · Cited by 123
Self-citationSlingluff, C. L., Petroni, G. R., Olson, W. C., Czarkowski, A. R., Grosh, W. W., Smolkin, M. E., Chianese‐Bullock, K. A., Neese, P. Y., Deacon, D. H., Nail, C. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3161 · Cited by 119
Liu, F., Park, P. J., Lai, W. R., Maher, E. A., Chakravarti, A., Durso, L. E., Jiang, X., Yu, Y., Brosius, A., Thomas, M. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1408 · Cited by 115
Butowski, N. A., Chang, S. M., Junck, L., DeAngelis, L. M., Abrey, L. E., Fink, K., Cloughesy, T. F., Lamborn, K. R., Salazar, A. Μ., & Prados, M. D. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9693-3 · Cited by 112
Self-citationFujita, M., Zhu, X., Ueda, R., Sasaki, K., Kohanbash, G., Kastenhuber, E. R., McDonald, H. A., Gibson, G. A., Watkins, S. C., Muthuswamy, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2915 · Cited by 108
Self-citationYKL-40 Is a Differential Diagnostic Marker for Histologic Subtypes of High-Grade Gliomas
Nutt, C. L., Betensky, R. A., Brower, M. A., Batchelor, T. T., Louis, D. N., & Stemmer-Rachamimov, A. O. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1601 · Cited by 103
Zhu, X., Fallert-Junecko, B., Fujita, M., Ueda, R., Kohanbash, G., Kastenhuber, E. R., McDonald, H. A., Liu, Y., Kaliński, P., Reinhart, T. A., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0876-3 · Cited by 95
Self-citationNishimura, F., Dusak, J. E., Eguchi, J., Zhu, X., Gambotto, A. A., Storkus, W. J., & Okada, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3825 · Cited by 94
Self-citationFunctional Heterogeneity of Vaccine-Induced CD8+ T Cells
Monsurrò, V., Nagorsen, D., Wang, E., Provenzano, M., Dudley, M. E., Rosenberg, S. A., & Marincola, F. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5933 · Cited by 88
Weber, J. S., Boswell, W. D., Smith, J. W., Hersh, E. M., Snively, J., Diaz, M. I., Miles, S., Liu, X., Obrocea, M., Qiu, Z., et al. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181611420 · Cited by 82
Butowski, N. A., Lamborn, K. R., Lee, B. L., Prados, M. D., Cloughesy, T. F., DeAngelis, L. M., Abrey, L. E., Fink, K., Lieberman, F. S., Mehta, M. P., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9705-3 · Cited by 79
Self-citationWatchmaker, P. B., Berk, E., Muthuswamy, R., Mailliard, R. B., Urban, J. A., Kirkwood, J. M., & Kaliński, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0902062 · Cited by 77
Polarized dendritic cells as cancer vaccines: Directing effector-type T cells to tumors
Kaliński, P., & Okada, H. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.002 · Cited by 75
Self-citationGilliet, M. F., Kleinhans, M., Lantelme, E., Schadendorf, D., Burg, G., & Nestle, F. O. (2003) · Blood · doi:10.1182/blood-2002-07-2274 · Cited by 59
Fallert, B. A., & Reinhart, T. A. (2002) · Journal of Virological Methods · doi:10.1016/s0166-0934(01)00378-0 · Cited by 45
Self-citationDefective Receptor Expression and Dendritic Cell Differentiation of Monocytes in Glioblastomas
Ogden, A. T., Horgan, D., Waziri, A. E., et al. (2006) · Neurosurgery · doi:10.1227/01.neu.0000233907.03070.7b · Cited by 45
Cited by
Cancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938
Self-citationDendritic cell-based immunotherapy
Sabado, R. L., Balan, S., & Bhardwaj, N. (2017) · Cell Research · doi:10.1038/cr.2016.157 · Cited by 927
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Okada, H., Weller, M., Huang, R., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 781
Self-citation
Metadata
- Authors
- Okada, H., Kalinski, P., Ueda, R., Hoji, A., Kohanbash, G., Donegan, T. E., Mintz, A. H., Engh, J. A., Bartlett, D. L., Brown, C. K., Zeh, H., Holtzman, M. P., Reinhart, T. A., Whiteside, T. L., Butterfield, L. H., Hamilton, R. L., Potter, D. M., Pollack, I. F., Salazar, A. M., & Lieberman, F. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-01-20
- Volume
- 29
- Issue
- 3
- Pages
- 330-336
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2137405984
- Cited by
- 567
- References
- 51
- FWCI
- 16.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.